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Background: Wilms tumours (WTs) are characterised by several hallmarks that suggest epimutations such as aberrant
DNA methylation are involved in tumour progression: loss of imprinting at 11p15, lack of recurrent mutations and
formation of nephrogenic rests (NRs), which are lesions of retained undifferentiated embryonic tissue that can give rise
to WTs.
Methods: To identify such epimutations, we performed a comprehensive methylome analysis on 20 matched trios of
micro-dissected WTs, NRs and surrounding normal kidneys (NKs) using Illumina Infinium HumanMethylation450 Bead
Chips and functionally validated findings using RNA sequencing.
Results: Comparison of NRs with NK revealed prominent tissue biomarkers: 629 differentially methylated regions, of
which 55% were hypermethylated and enriched for domains that are bivalent in embryonic stem cells and for genes
expressed during development (P = 2.49 × 10-5). Comparison of WTs with NRs revealed two WT subgroups; group-2
WTs and NRs were epigenetically indistinguishable whereas group-1 WTs showed an increase in methylation variability,
hypomethylation of renal development genes, hypermethylation and relative loss of expression of cell adhesion genes
and known and potential new WT tumour suppressor genes (CASP8, H19, MIR195, RB1 and TSPAN32) and was strongly
associated with bilateral disease (P = 0.032). Comparison of WTs and NRs to embryonic kidney highlighted the
significance of polycomb target methylation in Wilms tumourigenesis.
Conclusions: Methylation levels vary during cancer evolution. We have described biomarkers related to WT
evolution from its precursor NRs which may be useful to differentiate between these tissues for patients with
bilateral disease.Background
Wilms tumour (WT) is the most common paediatric
renal cancer with a prevalence of 1 in 10,000 [1]. Al-
though a few genes that predispose to an increased risk
of WT have been identified, the underlying mechanisms
of Wilms tumorigenesis remain largely uncharacterised.
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unless otherwise stated.mutation frequencies (WT1 (12%) [2], WTX (18%) [3],
CTNNB1 (15%) [2], DROSHA (12%) [4], TP53 (5%) [5])
and as most mutations often occur in the same tumour
[3,6], approximately 65% of WTs are negative for all com-
mon somatic mutations. Furthermore, a recent genome-
wide association study identified only two susceptibility
loci of genome-wide significance and moderate effect size
[7]. By contrast, up to two-thirds of WTs have abnormal-
ities at the imprinted IGF2/H19 locus on 11p15 and an
epigenetic biomarker common to 118 out of 120 WTs
identifiable in blood was found [8], indicating the possible
involvement of epimutations such as aberrant DNAl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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WT-specific differentially methylated regions (DMRs) at
GLIPR1 [10], imprinted genes NNAT [11] and the WT1-
antisense region [12], various satellite regions [13,14],
HACE1 [15], RASSF1A [16], P16 and the protocadherin
cluster at 5q31 [17].
In 40% of unilateral and almost 100% of bilateral cases,
nephrogenic rests (NRs) are found juxtaposed to WTs
and are considered precursor lesions [18]. NRs appear
morphologically as lesions reminiscent of embryonic
kidney (EK) retained from improper renal development
[18]. There are two types of NR, perilobar and intralo-
bar, that differ in terms of their location within the renal
lobe and their morphological features [18]. Analysis of
somatic aberrations found in WTs and their associated
NRs has not clearly implicated any of the known path-
ways in either persistence of these presumed precursor
lesions or their tumorigenic progression [19-22] and no
comprehensive epigenetic analysis has yet been under-
taken on NR lesions. This is largely due to the limita-
tions of NR samples, which are microscopic lesions
identified by histopathological review of formalin fixed
paraffin embedded (FFPE) tissue.
Although previous studies have implicated epigenetics,
embryonic or stem-like cells and disrupted renal devel-
opment in WT aetiology [23,24], a comprehensive longi-
tudinal analysis of tumour formation has not yet been
undertaken. Therefore, we conducted the first longitu-
dinal epigenetic study using NK, NR and WT trios to
gain new insights into the disruption in normal renal de-
velopment and the steps leading to transformation in
WTs.
Methods
Sample collection and DNA extraction
Use of patient samples in this study was conducted
with ethical approval granted by the NHS London
Bridge Research Ethics Committee (reference 12/LO/
0101) with experiments performed in compliance with
the Helsinki Declaration. Patients included in this study
were enrolled in the UK into the International Society
of Paediatric Oncology (SIOP) Wilms Tumour 2001
Clinical Trial and Study (clinical trial registration num-
ber: EUDRACT 2007-004591-39) with appropriate par-
ental consent and ethical approval. Post-nephrectomy
pathology reports were studied and from those indicat-
ing the presence of NRs, FFPE blocks of the nephrec-
tomy tissue were collected from the treatment centre.
Haematoxylin and eosin-stained 3 μm sections taken from
these FFPE blocks were examined independently by two
paediatric pathologists who identified clearly separated re-
gions of normal kidney (NK), NR and WT. Due to the dif-
ficulty in distinguishing between chemotherapy-treated
WT and NRs in a previous study [19], sample selectionwas meticulous. In total 36 NKs, 24 NRs (5 intralobar
NRs and 19 perilobar NRs) and 37 WTs were identified
including a total of 23 matched trios. Microdissection
was carried out by either a 2 μm core sample (for
blocks composed entirely of NK or WT) or by cutting
20 to 30 5-μm sections (dependent on region area) and
removing the desired tissue with a scalpel. DNA extraction
from FFPE tissue was carried out using the DNeasy Blood
& Tissue Kit (QIAGEN, Hilden, Germany). Manufacturer’s
instructions were modified with an additional 90°C heating
step for 1 hour after overnight incubation at 56°C and a
10 minute incubation at 70°C after adding AL buffer.
Genome-wide methylation analysis using Illumina 450 k
BeadChips
An optimised FFPE protocol was followed [25] whereby
0.5 to 2 μg DNA (depending on available yield) was
treated using the REPLIg FFPE kit (QIAGEN) and the
EZ DNA Methylation kit (Zymo Research Corp, CA,
USA). Methylation-specific primers were used to con-
firm bisulfite-conversion success of at least 98%. A total
of 97 samples were profiled using the Illumina Infinium
450 k platform [26]; these were processed by UCL Gen-
omics according to manufacturer’s instructions. The
scanned BeadChip microarray data were interpreted by
GenomeStudio software (v1.9.0, Illumina) and then ana-
lysed using R statistical software v3.02 [27]. Prior to stat-
istical analyses, data were filtered to remove samples
with low coverage and poor density profiles, resulting in
the exclusion of one NK, two NR and one WT sample,
leaving a total of 20 matched trios. Further quality con-
trol and data normalisation using the Bioconductor
package ChAMP [28] implemented the removal of all
probes where at least one sample showed poor detection
(detection P > 0.01), leaving 435,385 normalised β-values.
The 450 k methylation data described in this study are
available from the Gene Expression Omnibus with ac-
cession ID GSE59157.
Statistical analysis of methylation β-values
All statistical analyses were performed using R. To make
comparisons between tissues, the Bioconductor package
Limma [29] was used to generate a Bayesian framework
linear model that performed three-way contrasts be-
tween the tissue types for the ANOVA analysis. For
comparison of two tissue types, both histology type and
patient were considered in a Bayesian model which
made intra-patient comparisons at each CpG and then
compared these across all patients to generate average
Δβ values with corresponding P-values which were
corrected for multiple testing using the Benjamini-
Hochberg model [30]. DMRs were identified using the
Probed Lasso algorithm implemented through the Bio-
conductor package ChAMP [28]. This algorithm uses
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CpG for every probe and generates a category-specific
average probe density based on the CpG location. It
therefore considers the non-uniform distribution of
probes across the genome with large between-probe dis-
tances seen at intergenic regions and small distances
seen at TSS200 regions. From setting the minimum lasso
size to 10 bp, the algorithm calculates the respective
probe-lasso size within each category and centres this
lasso at each probe. Next, using the output topTable
from Limma, only those probes with a false discovery
rate (FDR) <0.01 were called significant. DMRs were
then defined if the lasso connected three or more signifi-
cant probes. Any non-significant probes within the lasso
region were also included in the DMR to better gauge
DMR significance and those DMRs within 1 kb of each
other were encompassed into one region.
To compare tissues avoiding cell type composition ef-
fects, the RefFreeEWAS algorithm was applied [31]; this
uses single value decomposition to estimate the number
of cell types contributing to overall histology. In this
study, the number of cell types contributing to methyla-
tion signal was estimated as d = 3. Using this parameter,
the algorithm deconvoluted the β-values using a design
matrix specifying patient pairs and sample histology, and
generated bootstrap-derived CpG-specific P-values (not
corrected for multiple testing) and covariates that cor-
respond only to a ‘phenotype-specific’ methylation signal
with no cell mixture effects as previously described [32].
To compare variance among groups, a Bartlett’s test
was run using R. Probe-wise comparisons were made to
assess the difference in variance between groups. Embry-
onic stem cell (ESC) chromatin data were extracted from
Gene Expression Omnibus/NCBI (accession ID GSE8463).
Enrichment of epigenetic or genetic features was deter-
mined by comparison of significant CpGs against an equal
sized cohort generated by multisampling all 450 k array
probes present after normalisation. To identify the fre-
quency of tumours with hypermethylated tumour suppres-
sor genes, tumours were classed as hypermethylated if the
average β-value for all CpGs in a DMR was greater than
the average for the NR cohort plus 1 standard deviation.
Pathway and gene ontology process analysis was conducted
using GREAT [33] with all CpGs present after normalisa-
tion used as a reference file. Processes with a significant
fold enrichment (>2) were selected with the Bonferroni
corrected P-value <0.01 and with at least four significant
genes per pathway.
Comparison with embryonic kidney
Human EKs were provided by the Joint MRC/Wellcome
Trust Human Developmental Biology Resource at the
UCL Institute of Child Health. Ethical approval was cov-
ered by the HDBR HTA tissue bank license and projectapproval. Details of approval terms can be found at [34].
DNA was extracted from four human EKs (from gesta-
tional age 8 weeks and 12 weeks) using the AllPrep
DNA/RNA Micro Kit (QIAGEN) according to the man-
ufacturer’s instructions. Methylation levels for EK were
derived using 450 k BeadChips as described above. The
20 trios plus 4 EKs were re-normalised together includ-
ing a between-array normalisation using wateRmelon
package Dasen to correct for between-array effects [35].
The final dataset included 330,731 CpGs with probes
that map to sex chromosomes, with known SNPs at the
target site or that bind multiple genomic loci (defined
from in silico analyses [36]) excluded. Comparisons be-
tween tissues were performed using Limma and
RefFreeEWAS with an unpaired design.
Validation by bisulfite sequencing
In total, 5 regions were selected for validation, which cov-
ered 18 CpGs interrogated by the 450 k array. Primers were
designed for bisulfite-converted DNA using MethPrimer
[37]. In total, 10 ng of bisulfite-converted FFPE extracted
DNA from four trios was used to amplify the specific gen-
omic regions. The hot-start enzyme KAPA HiFi Uracil +
(KAPA Biosystems Inc, Wilmington, MA, USA) was used
for PCR and products were cleaned using magnetic beads
(Beckman Coulter Inc, Brea, CA, USA) and quantified
using Picogreen reagents. Samples were tagged and pooled
prior to sequencing on the Illumina MiSeq according to the
manufacturer’s instructions.
Raw MiSeq paired-end reads were mapped to human
genome build hg19 with Bismark v0.9.0 [38] using Bowtie
2 [39] as the aligner. Methylated and unmethylated base
counts were generated with the bismark_methylation_
extractor utility and exported as BedGraph files for further
analysis and display in Integrative Genomics Viewer [40].
Aligned BAM files were sorted and indexed with SAM-
tools [41] for assessment of the regions of interest in
Integrative Genomics Viewer. The number of C reads
(methylated prior to conversion) was divided by the
total number of reads per bisulfite-sequenced CpG site
to discern the percentage methylation. These were then
compared with the respective 450 k β-values to com-
pare platforms.
RNA sequencing
RNA was extracted from 12 samples (4 trios) by cutting
multiple 5 μm sections of FFPE tissue and scraping the
target region using a new sterile scalpel blade each time.
Tissue was put into an Eppendorf then RNA was ex-
tracted using the RNeasy FFPE kit (QIAGEN) according
to the manufacturer’s instructions. Library preparation
for the 12 samples was performed using the TruSeq
RNA access kit (Illumina) and run on the Illumina Next-
Seq 500. Reads were aligned using TopHat2 [42] and
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excluded from the analysis due to poor read coverage
and aberrant clustering in unsupervised analysis. The
Bioconductor package DESeq [44] was used in R to
make group-wise comparisons between NK and NR,
then NR and WT, run with default parameters.
Results
Methylation profiles distinguish tissue types and show
increased variability in both NR and WT samples compared
to NK
To characterise tissue-specific methylation changes for
NK (n = 35), NRs (n = 22) and WTs (n = 36; including 20
matched trios) we derived methylation levels (β; 0 =
unmethylated, 1 = methylated) for 435,385 CpGs using
Illumina Infinium HumanMethylation450 BeadChips
and validated β-values using bisulfite-sequencing, which
showed good concordance (R = 0.8365, with a median
difference in β-value of 0.09; Figure S1 in Additional file
1; Additional file 2). Unsupervised clustering of the 1%
most variable CpGs (excluding probes that map to sex
chromosomes or with known SNPs at the target site;
termed XYS probes) revealed clear separation of samples
into tissue-related groups (Figure 1a), confirming the
significant association between tissue type and methyla-
tion. Although both intralobar NRs (n = 5) and perilobar
NRs (n = 17) were present, unsupervised analysis did not
distinguish between them and as sample groups were
small, we did not interrogate for further differences.
Next, we performed multidimensional scaling of the top
1% most variable CpGs to assess the inter-sample vari-
ability within each dataset. The NK samples grouped
tightly together; however, the NR and WT datasets both
showed high variability as illustrated by the wide disper-
sion of data points (Figure 1b). Furthermore, we found
that for probes showing significant non-homogeneity
of variances (Bartlett test), the vast majority exhibited
increased variance in NR and WT groups compared
with the NK group (NNK>NR = 9,334; NNR>NK = 94,546
and NNK>WT = 14,933; NWT>NK = 158,189; Figure S2 in
Additional file 1).
Supervised analysis reveals two Wilms tumour groups
As methylation status clearly distinguished between
tissue types (NK, NR and WT), we focussed on the set
of 20 matched trios (clinical information in Additional
file 3) and performed ANOVA on the full dataset with
XYS probes excluded to identify CpGs that were differ-
entially methylated between all three tissue types. This
analysis identified 7,921 CpGs reaching genome-wide
significance (P < 5 × 10-8). Upon clustering of these
CpGs, two clusters formed: cluster 1 (13 WT, 1 NR)
and cluster 2, which further separated into cluster 2a
(20 NK, 1 NR) and cluster 2b (7 WT, 18 NR; Figure 2).All NK samples fell into cluster 2a but the WT samples
fell into two distinct groups. Cluster 1 WT (termed
group-1 WT) appeared distinct from their NR whereas
cluster 2b WT (termed group-2 WT) clustered with
their respective precursor lesion. Upon further investi-
gation, we observed that all WTs from patients with
bilateral disease fell into group-1, giving a significant
association between distinction from NRs and bilateral
disease (P = 0.032, chi-square test). This was further
supported by re-evaluation of the unsupervised multi-
dimensional scaling analysis where group-2 WT ap-
peared closer to NR samples (Figure S3 in Additional
file 1). As this multidimensional scaling plot showed a
wider dispersion of group-1 WTs, a Bartlett test was
performed to compare levels of probe-specific variance
between group-1 and group-2 WTs. This test showed
that group-1 WTs had 2.4 times as many probes with a
significant increase in variance compared with group-2
WTs (31,638 compared with 13,124; P < 0.01), suggest-
ing that group-1 WTs have a more hypervariable
epigenome.
To further investigate whether two WT groups exist
that differ in terms of relationship with their respective
NRs, we separated group-1 (n = 13) and group-2 (n = 7)
WT-NR matched pairs and used a paired linear model
to identify intra-patient sites of differential methylation
that were common across samples. The matched study
design avoids patient-specific SNPs from giving false
positives and XYS probes were thus included. For
group-1 WT we identified 22,344 methylation variable
positions (MVPs; FDR <0.01). Conversely, group-2 WTs
showed no significant sites of differential methylation
compared with their associated NRs.
Wilms tumour cells show hypomethylation of key renal
development genes and silence tumour suppressor genes
by hypermethylation
Next, group-1 MVPs were grouped into discreet clus-
ters to further investigate their biological relevance
[28]. In total, 625 DMRs were identified, of which 460
(73.6%) were hypomethylated and 165 (26.4%) were
hypermethylated in WTs with respect to NRs; termed
hypo-WT-DMRs and hyper-WT-DMRs respectively.
Hyper-WT-DMRs were smaller and were more often
located at transcription start sites and within CpG
shores, indicating a relationship with tissue identity as
well as gene expression [45,46] (Table S3 in Additional
file 1). Conversely, hypo-WT-DMRs were enriched
within gene bodies and were not associated with CpG
islands, shores or shelves. By interrogation with GREAT
[33], which associates genomic positions with gene regula-
tory domains to infer biological significance, we found that
hypo-WT-DMRs were enriched within developmental
processes, including metanephric nephron development
Figure 1 Unsupervised analysis of methylation values in normal kidney (NK), nephrogenic rests (NR) and Wilms tumour (WT). (a) Unsupervised
consensus clustering of the top 1% most variable positions across the full dataset as determined based on interquartile range. Three clusters were formed
which predominantly separated tissue types. The 'Wilms tumour cluster' (dark red) is WT-predominant with 26 WT (pink) and 1 NR (blue) sample, which is
separated from the 'nephrogenic rest cluster' (navy) with 17 NR, 9 WT and 1 NK (green) sample and the 'normal kidney cluster' (dark green) with 34 NK, 4
NR and 1 WT sample. As the nephrogenic rest cluster contains several WT samples, some tumours may not be as epigenetically distinct from
their precursor lesions as suggested by their morphology. (b) Multidimensional scaling of the top 1% most variable positions showed greater
variability across the NR and WT datasets compared with NK.
Charlton et al. Genome Medicine  (2015) 7:11 Page 5 of 11and nephron development involving genes such as GDNF,
IRX2, PDGFB, POU3F3 and SOX8 and in processes in-
volved in stem cell maintenance, development and differ-
entiation (Table S4 in Additional file 1). Conversely,
hyper-WT-DMRs were enriched for genes involved in celladhesion processes and processes associated with regula-
tion of transcription (Table S5 in Additional file 1).
To demonstrate the effect on gene expression, RNA
sequencing was performed on four trios. Comparison
between NR and WT identified 75 genes with significant
Figure 2 ANOVA analysis identifies two Wilms tumour groups. Consensus clustering of the significant CpGs (n = 7,921; P < 5 × 10-8) from
ANOVA analysis of 20 trios of normal kidney (green), nephrogenic rest (blue) and Wilms tumour (pink). Here, three clusters can be seen which
show the presence of two distinct WT groups. Cluster 1 (grey) comprises group-1 WT (n = 13), which includes all bilateral WT (dark pink) and 4
unilateral cases (light pink). Group-1 WT clusters separately from their associated NRs. The second cluster further separates into two, with cluster
2a (purple) containing all NK samples and cluster 2b containing group-2 WTs (n = 7), which are all unilateral and cluster together with their
associated NRs.










CASP8 0.0037 10 of 13 104 20
H19 0.0045 11 of 13 NA NA
MIR195 0.0049 13 of 13 NA NA
RB1 0.0020 13 of 13 55 11
TSPAN32 0.0091 10 of 13 18 8
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volved in cell adhesion (CD200, GPR108, TSPAN2,
ADAMTS8, MDK and NCAM1) and in regulation of
transcription (NFKB1, MYSM1, PREPL; Table S6 in
Additional file 1). These data support the dysregulation of
these processes during progression from the precursor le-
sion, as identified by interrogation of hyper-WT-DMRs.
NCAM1 has previously been identified as being a marker
for cancer-propagating WTcells [47], suggesting its poten-
tial as a marker of transformation from NRs.
To identify methylation changes associated with trans-
formation, we studied the hyper-WT-DMRs further to
see whether we could link hypermethylation with
tumour suppressor gene silencing. Of the 123 genes as-
sociated with the 165 hyper-WT-DMRs, 5 were found
within TSgene, the Tumour Suppressor gene database
[48] and we predicted they would be inactivated in
group-1 WT (Table 1). Indeed, RNA sequencing showed
downregulation of CASP8, RB1 and TSPAN32 in WTs
compared with NRs (Table 1); however, due to small
sample numbers, these differences did not reachstatistical significance. As MIR-195 and H19 are a
miRNA and a non-coding RNA, respectively, these were
not detected by this assay. Of these, H19 DMR methyla-
tion (and hence presumed loss of imprinting) has been
previously reported in approximately 70% all WTs [2].
Here we see hypermethylation in 85% NR-associated
group-1 WT as an event associated with transformation.
For the 11 of 13 WT samples with gain of methylation
at H19, NK showed average methylation levels lower
than NRs (0.70 versus 0.78), both of which were
Figure 3 Hypermethylated KR-DMRs are enriched in developmental
loci and genes involved in β-catenin localisation. Hypermethylated
KR-DMRs showed 10.8% enrichment (empirical P≤ 0.01) for location
within domains that are bivalent in embryonic stem cells (considered
as developmental loci) compared with levels ascertained by repeated
multiple sampling of all array CpGs.
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P = 3.1 × 10-6, respectively), suggesting that, although a
major increase in methylation occurred upon trans-
formation, NK may contain a proportion of cells with
methylated H19 DMR as this imprinted region showed
higher than expected methylation levels.
Cell composition correction identifies 'pheno-MVPs'
Although the MVPs identified and described here are
valid tissue biomarkers that distinguish NRs from WTs
encompassing the heterogenous nature of each tissue,
these findings may also be due to the known variable cell
type composition (as shown in Figure S4 in Additional
file 1). To take this into consideration, the RefFreeEWAS
algorithm was applied to the 20 NR-WT pairs. This al-
gorithm uses single value decomposition to identify
changes in methylation associated with a cell mixture,
providing adjusted covariates and P-values that represent
direct epigenetic effects [31]. Such pheno-MVPs, as pre-
viously described [32], most accurately reflect pheno-
typic methylation changes. In total, 37,118 pheno-MVPs
were identified (P < 0.01). Of these, 12,929 (35%) were
hypermethylated and 24,189 (65%) were hypomethylated
in WTs with respect to NRs. As a cell-type composition
corrected β-value matrix cannot be generated by this
package, and no algorithm for DMR detection is in-
cluded, we cannot comment on whether the two groups
or the biomarker DMRs were detected as a result of cell
composition effects. Instead, we compared the MVPs
identified by each respective method and found that
9,651 (36%) of MVPs identified by the non-corrected
Limma algorithm were also detected by RefFreeEWAS.
Genes with the largest number of pheno-MVPs included
ARHGEF16, SIM2, H19, GALNT5, U6, ALG10, IRX4,
TBX15, VAX2, and PRRT1 and significantly overlapped
with genes showing polycomb-associated H3K27me3 in
normal tissue that gained methylation in cancer tissue [49]
(P = 9.11 × 10-126; 246 CpGs, identified using GREAT).
Aberrant hypermethylated DMRs in NR tissue suggest
developmental arrest
After demonstrating the presence of two WT groups
according to the epigenetic relationship to their associ-
ated NRs, we next focused on characterising the NR
methylome. There was no evidence of differences be-
tween NRs as 18 out of 20 fell into ANOVA cluster 2b
(Figure 2). Therefore, we performed linear modelling
on the 20 NK-NR pairs to identify methylation changes
associated with incomplete renal development. The
comparison between NK and NR identified 23,667 dif-
ferentially methylated MVPs (FDR <0.01), which were
grouped into 629 DMRs with relatively equal proportions
of hyper- and hypomethylation (55% and 45%, respect-
ively). We termed these kidney-rest DMRs (KR-DMRs;Table S7 in Additional file 1) with hypo-KR-DMR and
hyper-KR-DMR referring to hypomethylation and hyper-
methylation in the NRs with respect to NK. Analysis of
hypo-KR-DMRs did not result in overrepresentation of
any processes that could be readily associated with
developmental arrest (Table S8 in Additional file 1);
however, analysis of hyper-KR-DMRs, which were sig-
nificantly enriched within CpG shores (9.9%, empirical
P-value = 0.01), showed overrepresentation of develop-
mental or multicellular organismal processes (Table S9
in Additional file 1). The overrepresented processes in-
cluded early embryonic patterning, and we hypothesised
that gain of methylation may be occurring at developmen-
tal loci required to complete nephrogenesis.
To test this hypothesis, we explored the overlap be-
tween the hyper-KR-DMRs and regions of active chro-
matin (with chromatin mark H3K4me3) and regions of
repressed chromatin (with H3K27me3) in ESCs [50,51].
In ESCs, the combination of both marks (bivalent do-
mains) allows for loci to be poised in a state awaiting dif-
ferentiation signals that either rapidly repress or express
the underlying gene. Multisampling analysis revealed a
strong, significant enrichment of hyper-KR-DMRs within
bivalent domains (10.8%, empirical P = 0.01; Figure 3; by
comparison, hypomethylated KR-DMRs were negatively
enriched by -1.9%). As bivalent domains mark key devel-
opmental genes poised for differentiation, this positive
enrichment suggests that DNA hypermethylation may
contribute to the developmental arrest seen in NRs.
To take into consideration cell composition effects,
the RefFreeEWAS algorithm was also applied to the
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identified a total of 61,497 pheno-MVPs with 28,495
(46%) hypo- and 33,002 (54%) hypermethylated in NR
with respect to NK. In total, 69% non-corrected MVPs
overlapped with the pheno-MVPs. These pheno-MVPs
also showed a significant association with genes that are
H3K27me3 marked by polycomb proteins in normal tissue
that acquire cancer-specific methylation [49] (P = 1.76 ×
10-20; 141 CpGs).
Comparison with embryonic kidney shows aberrant gain
of methylation at Polycomb sites is not associated with
developmental stage
As the WT cell-of-origin is embryonic, methylation
levels were compared between EK (n = 4), NRs and
WTs. For these analyses, as we do not need to identify
tissue-specific biomarkers and the EK was not matched,
each comparison was performed using the RefFreeE-
WAS algorithm [31]. To begin with, we focussed on the
pheno-MVPs that differentiate between NRs and EK. As
previously mentioned, it was not possible to generate
DMRs using the RefFreeEWAS package and we there-
fore focussed on pheno-MVPs with P < 0.01 and Δβ >
|0.2|. Of the 4,457 MVPs identified in this comparison,
2,108 were hypo-MVPs and 2,349 were hyper-MVPs in
NRs with respect to EK. Although MVP selection here
was different from the previous DMR selection, similarly
to the NR-NK comparison, many of the hyper-MVPs fell
within key genes involved in renal development and
were therefore enriched in renal development processes.
Hyper-MVPs also showed a significant association with
regions identified as Polycomb repressive complex 2
(PRC2) targets in ESCs (P = 2.79 × 10-66) [52], including
a set of 189 genes and 480 CpGs (20% of hyper-MVPs).
This concordance of results between comparisons of
NRs with each of NK and EK suggests that the gain of
methylation observed here is a true aberrant event asso-
ciated with NR formation rather than an epigenetic fea-
ture reminiscent of an early developmental stage.
Next, we focussed on pheno-MVPs identified from
comparison of WTs with EK, of which 5,814 (44%) were
hypomethylated and 7,538 (56%) were hypermethylated
in WTs with respect to EK. We first focussed on WT
hyper-MVPs and, by interrogation with GREAT, identi-
fied similar developmental processes as identified in the
NR-EK comparison, suggesting maintenance of the epi-
genetic landscape from the NR. The surprising differ-
ence was that the WT-EK comparison highlighted many
more processes involved in general embryonic develop-
ment instead of specifically renal development, includ-
ing, for example, 228 genes involved in embryonic
pattern specification and 251 genes involved in embry-
onic morphogenesis (the most differentially methylated
included FOXD1, GLI2, HOXA5, HOXD10, LBX1, PAX2,SIM2, SIX3, TBX3, UNCX, VAX2 and WNT10A). Fur-
thermore, a significant enrichment was again seen for
hyper-MVPs within regions of PRC2 binding (P = 3.92 ×
10-217), but there was also a very significant enrichment
for regions of H3K27me3 (P = 2.91 × 10-247), Polycomb
EED targets (P = 1.08 × 10-241) and Suz12 targets (P =
8.65 × 10-207), all identified by ChIP on chip in human
ESCs [52]. This evidence suggests a further dysregula-
tion of methylation at Polycomb target sites and devel-
opmental loci as cells progress towards malignancy.
Discussion
In this study, we show that regional differences in DNA
methylation can discriminate between NK, NRs and
WTs. We highlight that both NRs and WTs have more
between sample variability than NK with increased vari-
ability associated with tumourigenesis, a finding consist-
ent with adult adenocarcinoma of the colon [9]. In this
study, NR formation, by comparison with NK and EK,
was associated with hypermethylation of genes involved
in renal development and loci that show bivalent chro-
matin marks in ESCs. Although this enrichment at bi-
valent domains suggests that DNA hypermethylation
may contribute to the developmental arrest seen in NRs,
recent evidence [53] suggests that bivalent marking is
more ubiquitous than previously thought, thus poten-
tially reducing its specificity as a marker for the poised
state, if confirmed. These same loci were PRC2 target
sites that show H3K27me3 in normal tissue and are
commonly methylated in other cancers. These similar
findings, in both non-corrected and corrected analyses
for cell type composition and in comparison with both
NK and EK tissues, suggests that the initiating step in
Wilms tumourigenesis - that is, NR retention in post-
natal kidney - involves PRC2-associated gain of methyla-
tion (either by an active or passive mechanism) at renal
development loci required for normal nephrogenic dif-
ferentiation, which is not cell composition-mediated.
NRs cannot, therefore, differentiate normally and remain
as aberrant embryonic-like tissue in the post-natal kid-
ney. Polycomb target hypermethylation has previously
been associated with the cancer phenotype and less
well-differentiated tumours [52]. It has been proposed
that the disruption of normal Polycomb mechanisms is
central to tumour initiation [54], and gain of methylation
has been detected in pre-malignant lesions for other
adult cancers [55].
Supporting the role of Polycomb protein dysregulation
in WTs, evidence from a mouse model of in vivo repro-
gramming associated formation of WT-like lesions with
failure of Polycomb gene targets to be repressed [56].
Furthermore, upregulation of Polycomb genes BMI-1,
EZH2, SUZ12 and EED was seen in progressive
blastemal-enriched WT xenografts in mice, suggesting
Charlton et al. Genome Medicine  (2015) 7:11 Page 9 of 11their expression correlated with tumourigenesis [57].
The question that remains is what causes PRC overex-
pression in the first place? Genetic mutation could be in-
volved and DNA sequencing projects are currently
underway that may highlight novel mutations in WTs
associated with Polycomb gene regulation.
This study presents novel evidence that WTs with as-
sociated NRs fall into two distinct subsets according to
whether they have a similar (group-2) or distinct (group-1)
methylome. We hypothesise that group-2 WTs may be
driven by somatic mutation and have a more stable epige-
nome that remains close to that of their precursor NR as
no significant common changes in methylation occur be-
tween WTs and NRs. Furthermore, as group-1 WTs sig-
nificantly associate with bilateral disease, we predict that
the event leading to NR formation occurs at an earlier time
point in embryogenesis as both kidneys are affected. We
therefore hypothesise that the progenitor cells within this
population are more epigenetically unstable, regardless of
their association with potentially epigenome-modifying
genetic mutations, which results in hypermethylation of
tumour suppressor genes, giving selective advantage and
causing transformation. CASP8 and H19 have been previ-
ously associated with WTs [58,59], and H19 in particular
has been associated with sporadic bilateral disease [2],
whereas RB1, Mir-195 and TSPAN32 aberrations have not
previously been identified in WTs, although detected in
other cancers [60-68]. This epigenetic plasticity will be rep-
licated in the tumour-initiating cell, which would allow the
resultant proliferating tumour to evolve into an entity with
a distinct epigenetic profile from the NR. This is supported
by evidence showing that group-1 tumours have a greater
number of significantly more variable probes than group-2
tumours. In group-1 WT we saw hypomethylation of genes
that, if expressed as predicted, give WTs an EK-like profile
similar to that observed in previous WTchromatin and ex-
pression profiling studies [23,24]. This study shows that
obtaining this phenotype is associated with the stage of
transformation and not with the precursor lesion. Also as-
sociated with transformation was gain of methylation at
H19. The H19 DMR showed high levels of methylation in
both NK and NRs, but levels significantly increased upon
transformation to WTs, which was not confounded by cell
type composition.
Conclusions
Methylation profiles vary significantly between NK, NRs
and WTs and changes in the methylome underlie both
NR formation and transformation to WTs in a subset of
cases. We have presented the first molecular association
between developmental arrest and NR formation and
showed the presence of two distinct WT groups by
methylome comparison with their associated NRs. These
genome-wide and gene-specific assays, which work wellon formalin-fixed tissue, have potential clinical utility to
distinguish more accurately between NRs and treated
WTs in patients with bilateral disease. This distinction,
which is often difficult to make unambiguously by histo-
logical examination, would be useful for post-operative
treatment planning (determining whether the resection
margin is clear of tumour, which dictates the need for
radiotherapy) and would aid in the evaluation of the effi-
cacy of nephron-sparing surgery in achieving complete
tumour excision. However, the potential use of a mo-
lecular marker for this purpose requires validation in an
independent set of cases. Finally, as group-1 tumours ap-
pear more epigenetically unstable, we propose that epi-
genetic modifiers be considered as candidate therapeutic
targets for WT and prevention of NR transformation in
pre-disposed individuals, particularly as few targeted
therapies have emerged to date based on somatic muta-
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